Personal experience of taking Ribocil/Kaillon for a year

In the field of targeted treatment of breast cancer, Ribociclib (Ribociclib), as an option, has gradually entered the field of vision of more patients. For patients who have used it for more than a year, the most intuitive feelings are often reflected in the drug's tolerance, maintenance of efficacy, and changes in quality of life. As a selective CDK4/6 inhibitor, ribociclib delays tumor development by blocking tumor cell cycle progression. When used in combination with drugs such as aromatase inhibitors or fulvestrant, patients can often achieve more durable disease control.

The experience of taking it for one year can be understood from three levels. First of all, in terms of efficacy experience, some patients will find that their condition is relatively stable, and the changes in imaging examinations and tumor markers are relatively stable, which increases their confidence in treatment. Second is the side effect experience. During long-term use of about a year, the more common reactions include leukopenia, fatigue, mild gastrointestinal discomfort, etc. Most patients can be improved through dosage adjustment or symptomatic treatment under the guidance of a doctor, and it will not completely affect their daily life. Thirdly, in terms of psychology and quality of life, many female patients gradually form regular medication habits after taking medication for one year, have a clearer understanding of the risks brought by drugs, and are better able to integrate treatment with the rhythm of life and maintain a balance between work and family.

It is worth noting that individual differences among patients are very obvious, and the so-called "personal experience" is not a one-size-fits-all answer. Some patients will be more concerned about the effects of drugs on physical strength, while others will be concerned about changes in their skin, mood, or menstrual cycle. Therefore, during one year of use, regular review of blood routine, liver and kidney function, and electrocardiogram are still key to ensure safety. Overseas research data shows that long-term adherence to treatment often leads to more impressive progression-free survival, but this clinical value needs to be weighed against individual tolerance.

Reference materials:https://us.kisqali.com/